402 related articles for article (PubMed ID: 37081880)
1. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
Tang Y; Li Y; Song T
Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
[TBL] [Abstract][Full Text] [Related]
2. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
[TBL] [Abstract][Full Text] [Related]
4. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
6. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
[TBL] [Abstract][Full Text] [Related]
8. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
[TBL] [Abstract][Full Text] [Related]
9. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
Young C; Papiro T; Greenberg JH
Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
[TBL] [Abstract][Full Text] [Related]
10. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients.
Wang AX; Koff A; Hao D; Tuznik NM; Huang Y
Am J Transplant; 2022 Aug; 22(8):2117-2119. PubMed ID: 35158412
[No Abstract] [Full Text] [Related]
11. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
[TBL] [Abstract][Full Text] [Related]
12. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
[TBL] [Abstract][Full Text] [Related]
14. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
Yang H; Yu X; Hou W; Liu X; Chen J; Zhang Y; Wang Y; Zhu Y; Qian Q; Ma K; An Z
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0138423. PubMed ID: 38289075
[TBL] [Abstract][Full Text] [Related]
16. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
[TBL] [Abstract][Full Text] [Related]
17. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
Shen D; Gong Y; Qian Y; Zhu J; Gao J
J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients.
Mendoza MA; Razonable RR
Infect Dis Clin North Am; 2023 Sep; 37(3):475-493. PubMed ID: 37142512
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
Sindelar M; McCabe D; Carroll E
J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]